Last reviewed · How we verify
HB0034
At a glance
| Generic name | HB0034 |
|---|---|
| Also known as | HB0034, a recombinant humanized anti-IL-36R IgG1 monoclonal antibody, Anti-IL-36R antibody,Recombinant Humanized anti-IL-36R Monoclonal antibody, Recombinant Humanized anti-IL-36R Monoclonal antibody, no other invention names |
| Sponsor | Shanghai Huaota Biopharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP) (PHASE2)
- Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis (PHASE2, PHASE3)
- A Study to Evaluate HB0034 in Healthy Chinese Adult Participants (PHASE1)
- A Study to Evaluate Multi-dose of HB0034 in Healthy Adult Participants (PHASE1)
- HB0034 in Patients With Generalized Pustular Psoriasis (GPP) (PHASE1)
- A Study to Evaluate HB0034 in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HB0034 CI brief — competitive landscape report
- HB0034 updates RSS · CI watch RSS
- Shanghai Huaota Biopharmaceutical Co., Ltd. portfolio CI